NMD Pharma develops small‑molecule inhibitors of the skeletal‑muscle‑specific ClC‑1 chloride ion channel to directly improve muscle excitability, strength, and fatigue resistance. Leveraging a proprietary electrophysiology platform, the company advances candidates for rare neuromuscular disorders such as myasthenia gravis, spinal muscular atrophy, Charcot‑Marie‑Tooth disease, and age‑related sarcopenia.
Funding
$81.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
3OJCFounders
Product
Problem
Patients with neuromuscular disorders such as myasthenia gravis, spinal muscular atrophy, Charcot‑Marie‑Tooth disease, and sarcopenia experience muscle weakness and fatigue due to impaired skeletal‑muscle activation, leading to reduced functional independence and quality of life. Existing therapies often target the nervous system or disease‑specific pathways but do not directly address the underlying muscle electrophysiology that contributes to symptom severity.
Solution
NMD Pharma leverages a proprietary electrophysiology platform to develop small‑molecule inhibitors of the skeletal‑muscle‑specific ClC‑1 chloride ion channel. By modulating ClC‑1 activity, these compounds aim to improve muscle excitability, increase strength, and reduce fatigue across a range of neuromuscular conditions. The lead candidate, ignaseclant (formerly NMD670), is in clinical development for Charcot‑Marie‑Tooth disease, generalized myasthenia gravis, and spinal muscular atrophy, with additional programs exploring age‑related sarcopenia and other rare disorders. The approach combines deep biological insight, high‑throughput small‑molecule screening, and validated in‑vivo pharmacology models to translate muscle‑specific biology into clinically meaningful functional improvements.
Target Audience
Primary customers are pharmaceutical partners, clinical researchers, and healthcare providers focused on rare neuromuscular diseases and age‑related muscle degeneration who require disease‑modifying therapies that act directly on skeletal‑muscle function.
Features
- Small‑molecule ClC‑1 chloride channel inhibitors designed for selective uptake in skeletal muscle
- First‑in‑class mechanism that directly enhances muscle excitability and reduces fatigue
- Integrated muscle electrophysiology platform enabling rapid target validation and pharmacodynamic readouts
- Robust preclinical and translational models that link ion‑channel modulation to functional strength outcomes
- Clinical pipeline covering multiple rare neuromuscular diseases (CMT, gMG, SMA) and broader age‑related muscle loss
- Proprietary drug‑discovery workflow combining high‑throughput screening, structure‑activity optimization, and in‑vivo efficacy testing